Document is current
Any future updates will be listed below
-
Authors
Maksemous, Neven
Harder, Aster V. E.
Ibrahim, Omar
Vijfhuizen, Lisanne S.
Sutherland, Heidi
Pelzer, Nadine
de Boer, Irene
Terwindt, Gisela M.
Lea, Rodney A.
van den Maagdenberg, Arn M. J. M.
Griffiths, Lyn R. https://orcid.org/0000-0002-6774-5475
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (APP1122387)
Migraine Research Foundation
International Australian Studies Association
Therapeutic Innovation Australia
The Centre of Medical System Biology (CMSB) in the framework of the Netherlands Genomics Initiative (050-060-409)
The European Community (EC) FP7-EUROHEADPAIN (602633)
- License Information
-
More Information
Article History
Received: 20 November 2022
Accepted: 2 February 2023
First Online: 14 February 2023
Change Date: 23 February 2023
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Human Research Ethics Committee of the Queensland University of Technology (approval number: 1800000611) and by the Medical Ethics Committee of LUMC.
: Appropriate consents for the patient cohort are already in place.
: Not applicable.
: GMT reports consultancy support from Novartis, Allergan/Abbvie, Lilly, and Teva, Lundbeck and independent support from Dutch Research Council, the Dutch Heart & Brain Foundations, IRRF and Dioraphte. AMJMvdM reports research support from Praxis Precision Medicine and Schedule 1 Therapeutics and consultancy support from AbbVie. LRG reports recent consultancy support from Teva and research support from the Australian National Health and Medical Research Council and the US Migraine Research Foundation. IdB reports independent support from the International Retinal Research Foundation and Dutch Heart Foundation. AVEH, LSV, OI, NP, NM, HS and RAL declare no conflict of interest.
